Next Article in Journal
[99mTc]Sestamibi SPECT Can Predict Proliferation Index, Angiogenesis, and Vascular Invasion in Parathyroid Patients: A Retrospective Study
Next Article in Special Issue
Management of Bleeding Events Associated with Antiplatelet Therapy: Evidence, Uncertainties and Pitfalls
Previous Article in Journal
Augmented Reality-Assisted Periosteum Pedicled Flap Harvesting for Head and Neck Reconstruction: An Anatomical and Clinical Viability Study of a Galeo-Pericranial Flap
Previous Article in Special Issue
A Morphometric Analysis of Platelet Dense Granules of Patients with Unexplained Bleeding: A New Entity of Delta-Microgranular Storage Pool Deficiency

Pathophysiology and Diagnosis of Drug-Induced Immune Thrombocytopenia

EA 7501-Groupe Innovation et Ciblage Cellulaire (GICC), Université François Rabelais, CEDEX 01, 37032 Tours, France
Laboratoire d’Hématologie-Hémostase, Hôpital Trousseau, CHRU Tours, CEDEX 09, 37044 Tours, France
Laboratoire d’Hématologie, CNHU de Cotonou, Cotonou 01 BP 386, Benin
Département d’Immunologie plaquettaire, Institut National de la Transfusion Sanguine (INTS), 75015 Paris, France
Equipe ETRES (Ethics, Research, Translations), Centre de Recherche des Cordeliers, UMRS 1138, INSERM, Sorbonne Université, Université de Paris, 75006 Paris, France
Author to whom correspondence should be addressed.
J. Clin. Med. 2020, 9(7), 2212;
Received: 25 June 2020 / Revised: 9 July 2020 / Accepted: 10 July 2020 / Published: 13 July 2020
Drug-induced immune thrombocytopenia (DITP) is a life-threatening clinical syndrome that is under-recognized and difficult to diagnose. Many drugs can cause immune-mediated thrombocytopenia, but the most commonly implicated are abciximab, carbamazepine, ceftriaxone, eptifibatide, heparin, ibuprofen, mirtazapine, oxaliplatin, penicillin, quinine, quinidine, rifampicin, suramin, tirofiban, trimethoprim-sulfamethoxazole, and vancomycin. Several different mechanisms have been identified in typical DITP, which is most commonly characterized by severe thrombocytopenia due to clearance and/or destruction of platelets sensitized by a drug-dependent antibody. Patients with typical DITP usually bleed when symptomatic, and biological confirmation of the diagnosis is often difficult because detection of drug-dependent antibodies (DDabs) in the patient’s serum or plasma is frequently not possible. This is in contrast to heparin-induced thrombocytopenia (HIT), which is a particular DITP caused in most cases by heparin-dependent antibodies specific for platelet factor 4, which can strongly activate platelets in vitro and in vivo, explaining why affected patients usually have thrombotic complications but do not bleed. In addition, laboratory tests are readily available to diagnose HIT, unlike the methods used to detect DDabs associated with other DITP that are mostly reserved for laboratories specialized in platelet immunology. View Full-Text
Keywords: platelets; thrombocytopenia; drugs; heparin-induced thrombocytopenia platelets; thrombocytopenia; drugs; heparin-induced thrombocytopenia
Show Figures

Figure 1

MDPI and ACS Style

Vayne, C.; Guéry, E.-A.; Rollin, J.; Baglo, T.; Petermann, R.; Gruel, Y. Pathophysiology and Diagnosis of Drug-Induced Immune Thrombocytopenia. J. Clin. Med. 2020, 9, 2212.

AMA Style

Vayne C, Guéry E-A, Rollin J, Baglo T, Petermann R, Gruel Y. Pathophysiology and Diagnosis of Drug-Induced Immune Thrombocytopenia. Journal of Clinical Medicine. 2020; 9(7):2212.

Chicago/Turabian Style

Vayne, Caroline, Eve-Anne Guéry, Jérôme Rollin, Tatiana Baglo, Rachel Petermann, and Yves Gruel. 2020. "Pathophysiology and Diagnosis of Drug-Induced Immune Thrombocytopenia" Journal of Clinical Medicine 9, no. 7: 2212.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop